Dear Bob, Are you serious. 1b in abraxane sales in just breast. Good luck with that. I can't wait to see what are quotas are going to be. No new data, raise the price that will work. It all about refocusing ... right Mark..... you are an idiot!! I am out soon anyway. Should be fun running up the tab next week. Love Abraxane reps
Did you hear him on the earnings conference call with the analysts? How can someone use so many words to say nothing. Wall street is reading right through the leadership. They expected that they would not hit the pfs in lung WTF!!!. You really think pancreatic is going to pan out? Get real. Patrick hoodwinked you guys. But at least his cvr s will end up being worthless. That was a good move. But if you really think by just refocusing on mbc you are going to get sustainable growth you are dreaming. Of course next quarter will be better. You sand bagged 4q abraxane sales. You have a great 1q and say look how good we are. The real test comes 3q and 4q with no new data, no new indication, and customers see that. Abraxane will continue to sell just not grow. But they can play with the numbers. The good thing is you have actually analysts covering this stock. Look at how many questions that had about Abraxane when it represents such a small amount of revenue. This is going to be really ugly come 4q. They will put you in a headlock until you admit that Uncle Patrick got one over on you. At least the lakers are struggling hahaha. Or you will soon start to sing “oh but we have the nab platform song” hahaha I am really worried they are going to crank some big time quotas on us. I remember in Chicago last year Shawn was so amazed that we did not get our quotas on time and said that would never happen with Celgene. But here we go again. Oh well I had already started to look around anyway. But I figure i can ride this gravy train for another quarter or so. Boy I wish I had gotten cut. I really thought they were going to bring new ideas and energy to the brand. But it is just the same old stuff with a BIG PHARMA twist. Mark is good guy actually. High energy. Just over his head. Watch how nasty things get in the summertime. Hopefully I will be gone by then. Not until I milk it a little more though. Hahahah.
shawn has no idea what she is talking about. Quotas were given after the Abraxis team actually received a forecast from Patrick. How could you give quotas when JH, JD and everyone else had to battle with Patrick. It all worked out OK, what is the national percent to plan? Is the nation not hitting its goal? I would bet that will not happen again next year. Shawn will start telling people they suck almost immediately. She wont learn the drug, the market or anything about anyone on the team unless they act like a puppy.
ITS GOING TO GET REALLY REALLY UGLY CHICAGO, Feb. 3, 2011 /PRNewswire/ -- Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List – Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): Greenhill & Co., Inc. (NYSE: GHL) and Electronic Arts Inc. (Nasdaq: ERTS). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: AMCOL International Corporation (NYSE: ACO) and Celgene Corporation (Nasdaq: CELG). To see the full Zacks #5 Rank List - Stocks to Sell Now visit: http://at.zacks.com/?id=92 Here is a synopsis of why ACO and CELG have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next one to three months. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks; AMCOL International Corporation (NYSE: ACO) announced fourth-quarter earnings of 21 cents per share on January 28 that lagged analysts' expectations by nearly 45%. The diluted earnings per share dipped 15% on a year-over-year basis. For 2011, the Zacks Consensus Estimate stands at a profit of $1.96 per share that dropped 8 cents over the past week as 3 out of the 4 covering analysts slashed projections. Next year's estimate moved down 6 cents to $2.35 per share in the same period. Celgene Corporation (Nasdaq: CELG) posted fourth-quarter earnings of 65 cents per share on January 27, which came in 3% short of the average forecast. The Zacks Consensus Estimate for 2011 declined 7 cents to $3.02 per share over the past month as 6 analysts out of 11 cut back on expectations. Estimate for 2012 dipped 10 cents to $3.71 per share in a span of a week.
The billion includes China, Europe -wake up guys You US reps are a bunch of whiners. Get with it guys. The launch in China is going better than anyone thinks. Patrick got this approved in Europe and never launched it. CELG is doing it in record time. You are finally with a world class organization. Just watch this earnings call on Oct 27th. There is a reason CELG hit a new high this week.
